Clinical Research Directory

Inclusion Criteria: * Age 0-25 years. * Newly diagnosed active disease or unstable disease (ongoing attacks despite treatment), whether genetically confirmed or still undiagnosed. * The patient or their legal representative provides informed consent to participate in the study, including undergoing omics analyses and agreeing to the sharing and use of their clinical and omics data for subsequent analyses. * Monogenic SAID: Patients with clinical and genetic findings consistent with a monogenic SAID belonging to one of the following categories: inflammasomopathies, unfolded protein response (UPR) and cellular stress disorders, type I interferonopathies, actinopathies, NF-κB hyperactivation disorders, or DADA2. Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels. * Multifactorial/complex SAID: Patients with clinical manifestations consistent with PFAPA, SURF (as defined in Papa R et al., 2020), chronic recurrent multifocal osteomyelitis (CRMO)/SAPHO syndrome, or systemic juvenile idiopathic arthritis (sJIA). PGA \> 2 on a 0-10 VAS and elevated CRP levels. * Undifferentiated SAID (uSAID): Patients with clinical manifestations consistent with a SAID, after exclusion of defined monogenic or multifactorial/complex autoinflammatory diseases based on clinical and/or genetic findings. PGA \> 2 on a 0-10 VAS and elevated CRP levels. * Fibromyalgia (FM): Widespread pain with symptoms present for at least 3 months. Patients meeting the clinical criteria defined in Wolfe et al. (2016). Exclusion Criteria: * Inflammatory bowel diseases or other inflammatory conditions that may mimic SAIDs (e.g., haematological disorders, malignancies, and immunodeficiencies).